About Raman & Weil Private Limited
Data last updated:
Raman & Weil Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 July 1988 and has been in existence for over 38 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24200MH1988PTC048181. Its GSTIN is 27AAACR5065M2Z0 (Maharashtra). The company holds 12 GST registrations, of which 6 are active.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹4.26 Lakh. It is led by directors Hiten Pravin Shah (Managing Director) and Bhowli Nikhil Shah.
Its last annual general meeting (AGM) was held on 28 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 36/37 3rd Floor Mittal Chamber Opp. Inox Theatre Nariman Point, Mumbai, Maharashtra, India – 400021.
As per the financials filed for FY 2025, the company reported a revenue of ₹145.87 Cr, a growth of 7% compared to the previous year. For the same year it recorded a net profit of ₹14.33 Cr (net margin 9.8%) and EBITDA of ₹22.92 Cr (EBITDA margin 15.7%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years.
The company has about 169 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹21.76 Cr and satisfied charges of ₹17.9 Cr on record. Court records list 12 cases involving the company, including 9 filed by the company and 3 filed against it; 2 cases are pending. The company has 5 deals on record (5 secondary share transfers); the latest was in February 2024. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Bafna Pharmaceuticals Limited with revenue of ₹148.6 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ramanweil.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address36/37 3rd Floor Mittal Chamber Opp. Inox Theatre Nariman Point, Mumbai, Maharashtra, India – 400021
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Raman & Weil Private Limited
The main business activity of Raman & Weil is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Raman & Weil Private Limited FY 2025 filings available
Raman & Weil Private Limited reported revenue of ₹145.87 Cr (up 7% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Raman & Weil Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 2% over three years, including 7% growth in the latest year. EBITDA fell 2% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Raman & Weil Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹22.92 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹14.33 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Raman & Weil Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 15.7% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 9.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Raman & Weil are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Raman & Weil Private Limited
Raman & Weil Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Bafna Pharmaceuticals Limited Listed | ₹148.6 Cr (FY 2025) | •••• | •••• | -5.0% | •••• | Chennai, Tamil Nadu, India |
| Celon Laboratories Private Limited | ₹148.17 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | Hyderabad, Telangana, India |
| Unosource Pharma Limited | ₹147.51 Cr (FY 2025) | •••• | •••• | 14.0% | •••• | Delhi, India |
| Canton Laboratories Private Limited | ₹147.08 Cr (FY 2025) | •••• | •••• | 26.0% | •••• | Vadodara, Gujarat, India |
| Murli Krishna Pharma Private Limited | ₹146.68 Cr (FY 2025) | •••• | •••• | -21.0% | •••• | Pune, Maharashtra, India |
| Raman & Weil Private Limited this company | ₹145.87 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Mumbai, Maharashtra, India |
| Pulse Pharmaceuticals Private Limited | ₹145.08 Cr (FY 2024) | •••• | •••• | -1.0% | •••• | Hyderabad, Telangana, India |
| HBC Lifesciences Private Limited | ₹144.64 Cr (FY 2024) | •••• | •••• | 17.0% | •••• | Gandhinagar, Gujarat, India |
| Goodway Chemicals Private Limited | ₹144.1 Cr (FY 2025) | •••• | •••• | -12.0% | •••• | Mumbai, Maharashtra, India |
| Afrinext Overseas Private Limited | ₹144.02 Cr (FY 2025) | •••• | •••• | 65.0% | •••• | Vadodara, Gujarat, India |
| Immacule Lifesciences Private Limited | ₹143.18 Cr (FY 2025) | •••• | •••• | 34.0% | •••• | Nalagarh, Himachal Pradesh, India |
Peers are the five companies nearest above and the five nearest below Raman & Weil by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Raman & Weil Private Limited
Raman & Weil Private Limited is audited by F K MODY & CO for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| F K MODY & CO | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Raman & Weil Private Limited
Raman & Weil has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bhowli Nikhil Shah | Director | 21 Jul 1988 | 38 Years 2 Months | Current |
| Hiten Pravin Shah | Managing Director | 04 Apr 2005 | 21 Years 6 Months | Current |
Ownership and Shareholding of Raman & Weil Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Raman & Weil Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Feb 2026 | Others | ₹50 Lakh | Open |
| 28 Jan 2026 | Others | ₹21 Cr | Open |
| 10 Jun 2025 | Others | ₹2.62 Lakh | Open |
| 10 Jun 2025 | Others | ₹21.66 Lakh | Open |
| 03 May 2025 | Others | ₹1.8 Lakh | Open |
Total charge records: 11 View all charges
Deals & Funding of Raman & Weil Private Limited
Raman & Weil Private Limited has 5 deals on record (5 secondary share transfers); the latest was in February 2024.
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2024 | Secondary share transfer | Undisclosed | Seller: 4 individuals |
| Feb 2020 | Secondary share transfer | Undisclosed | Seller: Ramanlal Finance and Investments Pvt Ltd , 2 individuals |
| Jan 2020 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: 2 individuals |
| May 2013 | Secondary share transfer | Undisclosed | Seller: 2 individuals |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
Full deal history
All 5 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Raman & Weil Private Limited
Raman & Weil Private Limited has 12 court cases on record: 9 filed by Raman & Weil, 3 filed against it. 2 cases are pending and 10 are disposed. Status as checked between 28 Sep 2026 and 05 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 7 | 1 | 1 |
| District courts | 3 | 1 | 1 |
| Supreme Court | 2 | 1 | 0 |
Cases on record (5 of 12)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Writ petition | Filed against the company by Neon Laboratories Limited | Disposed |
| Supreme Court | Appeal | Filed against the company by Neon Laboratories Limited | Disposed |
| Supreme Court | Court case | Filed by the company against Sirmaxo Chemicals Pvt Ltd | Disposed |
| District court, Maharashtra Industrial and Lab, Maharashtra | Interim or miscellaneous application | Filed by the company against Deputy Director Employees State Insurance Corporation | Pending |
| High Court of Punjab and Haryana | Criminal miscellaneous application | Filed by the company against State of Haryana | Pending |
Full case history
All 12 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Raman & Weil Private Limited
Raman & Weil Private Limited has a workforce of 169 employees as of Apr 08, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Raman & Weil Private Limited
Raman & Weil Private Limited has 6 board changes on record since 1988: 4 appointments and 2 cessations. The latest: Adimoolam Ramakrishna ceased to be Director on 01 Apr 2019.
19 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Raman & Weil Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Raman & Weil Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Raman & Weil Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Raman & Weil Private Limited
Raman & Weil has 12 GST registrations: 6 active and 6 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACR5065M2Z0 | Maharashtra | Active | 02 Aug 2017 |
| 27AAACR5065M3ZZ | Maharashtra | Active | 01 Sep 2023 |
| 36AAACR5065M1Z2 | Telangana | Active | 01 Jul 2017 |
| 26AAACR5065M1Z3 | Dadra and Nagar Haveli and Daman and Diu | Active | 01 Aug 2020 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Raman & Weil Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Raman & Weil Private Limited
Raman & Weil is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 July 1988 (38+ years old) and is registered under CIN U24200MH1988PTC048181.
Raman & Weil reported revenue of ₹145.87 Cr for FY 2025 (up 7% YoY).
Raman & Weil has 2 current directors:
- Hiten Pravin Shah - Managing Director
- Bhowli Nikhil Shah - Director
Raman & Weil reported a net profit of ₹14.33 Cr (net margin 9.8%) and EBITDA of ₹22.92 Cr (EBITDA margin 15.7%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Raman & Weil is 2% over three years. In the latest year (FY 2025) revenue rose 7%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Raman & Weil is 27AAACR5065M2Z0, registered in Maharashtra. The company has 12 GST registrations in all, of which 6 are active and 6 are cancelled or inactive. Other active GSTINs include 27AAACR5065M3ZZ (Maharashtra), 36AAACR5065M1Z2 (Telangana), 26AAACR5065M1Z3 (Dadra and Nagar Haveli and Daman and Diu).
The CIN (Corporate Identification Number) of Raman & Weil is U24200MH1988PTC048181. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Raman & Weil has 12 court cases on record: 9 filed by the company and 3 filed against it. 2 are pending. Most are in the high courts.
Raman & Weil was incorporated on 21 July 1988, making it 38+ years old. It is registered with the Registrar of Companies, Mumbai.
Raman & Weil has 5 deals on record (5 secondary share transfers); the latest was in February 2024.
The peers of Raman & Weil by revenue are Bafna Pharmaceuticals Limited, Celon Laboratories Private Limited, Unosource Pharma Limited, Canton Laboratories Private Limited, Murli Krishna Pharma Private Limited and 5 more, all in the Pharma industry (Formulations).